Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat versus best available therapy in adults with polycythemia vera after inadequate response or intolerance to hydroxyurea
MOH_2026-08-25_017004Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in polycythemia vera (PV) (2 arms), sponsored by Merck & Co. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
bomedemstat
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on MOH_2026-08-25_017004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-25_017004.